Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Dörner

Showing results (1-10 of 341) with videos related to

Pageof 35
Sort By:
Annals of the Rheumatic Diseases|September 23, 2020
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?Thomas Dörner
The New England Journal of Medicine|June 3, 2026
Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related DiseaseThomas Dörner
Arthritis Research & Therapy|September 6, 2011
Challenges in understanding Sjögren's syndrome--improved insights into the pathogenesis generate hope for innovative therapies?Thomas Dörner
The Journal of Rheumatology. Supplement|May 3, 2006
Crossroads of B cell activation in autoimmunity: rationale of targeting B cellsThomas Dörner
Nature Reviews. Rheumatology|January 11, 2012
SLE in 2011: Deciphering the role of NETs and networks in SLEThomas Dörner
Nature Reviews. Rheumatology|January 5, 2010
Therapy: Hydroxychloroquine in SLE: old drug, new perspectivesThomas Dörner
Deutsche Medizinische Wochenschrift (1946)|May 29, 2018
[Systemic Lupus Erythematosus (SLE) - New Classification Criteria]Martin Aringer, Thomas Dörner
Arthritis Research & Therapy|November 13, 2004
Autoantibodies in normals--the value of predicting rheumatoid arthritisThomas Dörner, Arne Hansen
Arthritis Research & Therapy|July 5, 2011
Considering comorbidity in managing rheumatic diseases: going where trials cannot goDaniel Aletaha, Thomas Dörner
Nature Reviews. Rheumatology|August 19, 2015
Biosimilars in rheumatology: current perspectives and lessons learntThomas Dörner, Jonathan Kay
Pageof 35

Showing results (1-10 of 341) with videos related to

Sort By:
Pageof 35
Annals of the Rheumatic Diseases|September 23, 2020
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?Thomas Dörner
The New England Journal of Medicine|June 3, 2026
Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related DiseaseThomas Dörner
Arthritis Research & Therapy|September 6, 2011
Challenges in understanding Sjögren's syndrome--improved insights into the pathogenesis generate hope for innovative therapies?Thomas Dörner
The Journal of Rheumatology. Supplement|May 3, 2006
Crossroads of B cell activation in autoimmunity: rationale of targeting B cellsThomas Dörner
Nature Reviews. Rheumatology|January 11, 2012
SLE in 2011: Deciphering the role of NETs and networks in SLEThomas Dörner
Nature Reviews. Rheumatology|January 5, 2010
Therapy: Hydroxychloroquine in SLE: old drug, new perspectivesThomas Dörner
Deutsche Medizinische Wochenschrift (1946)|May 29, 2018
[Systemic Lupus Erythematosus (SLE) - New Classification Criteria]Martin Aringer, Thomas Dörner
Arthritis Research & Therapy|November 13, 2004
Autoantibodies in normals--the value of predicting rheumatoid arthritisThomas Dörner, Arne Hansen
Arthritis Research & Therapy|July 5, 2011
Considering comorbidity in managing rheumatic diseases: going where trials cannot goDaniel Aletaha, Thomas Dörner
Nature Reviews. Rheumatology|August 19, 2015
Biosimilars in rheumatology: current perspectives and lessons learntThomas Dörner, Jonathan Kay
Pageof 35